Clinuvel Pharmaceuticals
CUVL
Clinuvel Pharmaceuticals (CUVL) earnings history
Most recent quarter
- Fiscal period
- Q4 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.35
- EPS estimate
- $0.35
- EPS surprise
- −0.97%
- Revenue surprise
- +3.63%
- Revenue
- $43.8M
- Revenue estimate
- $42.2M
- Reported
- Aug 27, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2026 | Aug 27, 2026 | $0.35 | $0.35 | −0.97% | $43.8M | SEC |
Quarterly revenue
Frequently asked questions
When did Clinuvel Pharmaceuticals (CUVL) last report earnings?
Clinuvel Pharmaceuticals last reported on Aug 27, 2026, covering fiscal Q4 2026.
Did CUVL beat earnings estimates?
No. Clinuvel Pharmaceuticals reported EPS of $0.35 for Q4 2026 against a $0.35 estimate — a 0.97% miss.
How much revenue did CUVL report last quarter?
Clinuvel Pharmaceuticals reported $43.8M in revenue for Q4 2026, against a consensus estimate of $42.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.